Literature DB >> 33687492

Prognostic Significance of Myocardial Ischemia Detected by Single-Photon Emission Computed Tomography in Children with Hypertrophic Cardiomyopathy.

Lidia Ziolkowska1, Agnieszka Boruc2, Dorota Sobielarska-Lysiak3, Agnieszka Grzyb2, Joanna Petryka-Mazurkiewicz4,5, Łukasz Mazurkiewicz4, Grazyna Brzezinska-Rajszys2.   

Abstract

Myocardial ischemia caused by microvascular dysfunction is an important pathophysiologic component of hypertrophic cardiomyopathy (HCM), promoting myocardial fibrosis, adverse left ventricular remodeling, and impacting on clinical course and outcome in HCM patients. The aim of study was to assess the prevalence and clinical significance of myocardial ischemia in children with HCM using 99mTc-MIBI single-photon emission computed tomography (SPECT). Ninety-one children with HCM, median age 13.6 years, underwent SPECT evaluation from 2006 to 2017. Imaging was performed at rest and after maximal exercise. Myocardial perfusion defects were identified in 70 children (76.9%; group I), median age 13.8 years. Fixed perfusion defects were evident in 22 of them, while reversible at rest in 48. In 21 children (23.1%; group II), median age 11 years, myocardial perfusion defects were not detected. Patient demographics, echocardiography, resting electrocardiogram (ECG), 24-h Holter ECG, myocardial fibrosis in cardiovascular magnetic resonance imaging, and cardiovascular events were analyzed and compared between the groups. During follow-up at a median of 8.3 years in children with myocardial ischemia, clinical endpoints occurred more often (47 vs. 5; p = 0.02) and more patients reached a clinical endpoint (28 [40%] vs. 3 [14.3%]; p = 0.036). In children with myocardial ischemia, myocardial fibrosis was observed with greater frequency. Myocardial perfusion defects may reflect an ischemic process which (1) affects the clinical manifestations and (2) is an important predictor of adverse clinical events and risk of death in children with HCM. Myocardial ischemia in HCM patients frequently correlates with myocardial fibrosis.

Entities:  

Keywords:  Children; Hypertrophic cardiomyopathy; Myocardial ischemia; Prognosis

Year:  2021        PMID: 33687492     DOI: 10.1007/s00246-021-02570-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  35 in total

1.  Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study.

Authors:  Alan W Nugent; Piers E F Daubeney; Patty Chondros; John B Carlin; Steven D Colan; Michael Cheung; Andrew M Davis; C W Chow; Robert G Weintraub
Journal:  Circulation       Date:  2005-08-22       Impact factor: 29.690

2.  Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry.

Authors:  Steven E Lipshultz; E John Orav; James D Wilkinson; Jeffrey A Towbin; Jane E Messere; April M Lowe; Lynn A Sleeper; Gerald F Cox; Daphne T Hsu; Charles E Canter; Juanita A Hunter; Steven D Colan
Journal:  Lancet       Date:  2013-09-03       Impact factor: 79.321

3.  Myocardial perfusion abnormality in the area of ventricular septum-free wall junction and cardiovascular events in nonobstructive hypertrophic cardiomyopathy.

Authors:  Satoshi Kaimoto; Tatsuya Kawasaki; Toshiro Kuribayashi; Michiyo Yamano; Shigeyuki Miki; Tadaaki Kamitani; Hiroaki Matsubara
Journal:  Int J Cardiovasc Imaging       Date:  2011-12-21       Impact factor: 2.357

4.  Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry.

Authors:  Steven D Colan; Steven E Lipshultz; April M Lowe; Lynn A Sleeper; Jane Messere; Gerald F Cox; Paul R Lurie; E John Orav; Jeffrey A Towbin
Journal:  Circulation       Date:  2007-01-29       Impact factor: 29.690

5.  Myocardial blood flow and fibrosis in hypertrophic cardiomyopathy.

Authors:  Giovanni Donato Aquaro; Giancarlo Todiere; Andrea Barison; Elisabetta Strata; Mario Marzilli; Alessandro Pingitore; Massimo Lombardi
Journal:  J Card Fail       Date:  2011-02-26       Impact factor: 5.712

6.  The incidence of pediatric cardiomyopathy in two regions of the United States.

Authors:  Steven E Lipshultz; Lynn A Sleeper; Jeffrey A Towbin; April M Lowe; E John Orav; Gerald F Cox; Paul R Lurie; Kristina L McCoy; Melissa A McDonald; Jane E Messere; Steven D Colan
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  The epidemiology of childhood cardiomyopathy in Australia.

Authors:  Alan W Nugent; Piers E F Daubeney; Patty Chondros; John B Carlin; Michael Cheung; Lynette C Wilkinson; Andrew M Davis; Stephen G Kahler; C W Chow; James L Wilkinson; Robert G Weintraub
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

8.  Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry.

Authors:  James D Wilkinson; April M Lowe; Bonnie A Salbert; Lynn A Sleeper; Steven D Colan; Gerald F Cox; Jeffrey A Towbin; David M Connuck; Jane E Messere; Steven E Lipshultz
Journal:  Am Heart J       Date:  2012-08-09       Impact factor: 4.749

9.  Comparison of echocardiography with tissue Doppler imaging and magnetic resonance imaging with delayed enhancement in the assessment of children with hypertrophic cardiomyopathy.

Authors:  Lidia Ziółkowska; Joanna Petryka; Agnieszka Boruc; Wanda Kawalec
Journal:  Arch Med Sci       Date:  2016-06-07       Impact factor: 3.318

10.  Predictors of Long-Term Outcome in Children with Hypertrophic Cardiomyopathy.

Authors:  Lidia Ziółkowska; Anna Turska-Kmieć; Joanna Petryka; Wanda Kawalec
Journal:  Pediatr Cardiol       Date:  2015-11-02       Impact factor: 1.655

View more
  1 in total

1.  Nuclear Imaging in Pediatric Cardiology: Principles and Applications.

Authors:  Maelys Venet; Mark K Friedberg; Luc Mertens; Jerome Baranger; Zakaria Jalal; Ghoufrane Tlili; Olivier Villemain
Journal:  Front Pediatr       Date:  2022-07-06       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.